RxDoctor Payments Data

Kameron Murray

Physician Assistant · Holdrege, NENPI 1174248389

Payments from drug & device makers

$1,694in general payments, 2019–2025

Across 71 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$746
  • AbbVie$272
  • Novo Nordisk$154
  • Amgen$137
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$85
  • Insulet Corporation$57
  • plus $243 from 10 others

What the payments were for

  • Food & beverage$1,694100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,694 in reported general payments places this provider in the 75th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$4,148
Medicare patients
19
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$23,615
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,117
FarxigaDapagliflozin Propanediol19$10,838
XareltoRivaroxaban25$7,975
LinzessLinaclotide14$7,100
JardianceEmpagliflozin11$5,845
Incruse ElliptaUmeclidinium Bromide11$3,830
SynthroidLevothyroxine Sodium25$812
Levothyroxine Sodium135$762
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen80$722
Meloxicam88$640
Gabapentin31$541
Cefdinir28$491
Atorvastatin Calcium91$471
Tramadol Hcl102$461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Farxiga$746$23,95540 claims
PfizerEliquis$27$23,61537 claims
AbbVieLinzess, Synthroid$272$7,91139 claims
Boehringer IngelheimJardiance$13$5,84511 claims
GSKIncruse Ellipta$14$3,83011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Holdrege

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →